A new peptide ligand for colon cancer targeted delivery of micelles

References

• Arias JL. (2011). Drug targeting strategies in cancer treatment: an overview. Mini Rev Med Chem 11:1–17
   PubMed Web of Science ®Google Scholar
• Baglia FA, Badellino KO, Ho DH, et al. (2000). A binding site for the kringle II domain of prothrombin in the apple 1 domain of factor XI. J Biol Chem 41:31954–62
   Web of Science ®Google Scholar
• Carvalho C, Santos RX, Cardoso S, et al. (2009). Doxorubicin: the good, the bad and the ugly effect. Curr Med Chem 16:3267–85
   PubMed Web of Science ®Google Scholar
• Chao C, Lotz MM, Clarke AC, Mercurio AM. (1996). A function for the integrin alpha6beta4 in the invasive properties of colorectal carcinoma cells. Cancer Res 56:4811–19
   PubMed Web of Science ®Google Scholar
• Chen D, Lian S, Sun J, et al. (2014). Design of novel multifunctional targeting nano-carrier drug delivery system based on CD44 receptor and tumor microenvironment pH condition. Drug Deliv 3:1–6
   Web of Science ®Google Scholar
• Cox D, Brennan M, Moran N. (2010). Integrins as therapeutic targets: lessons and opportunities. Nat Rev Drug Discov 9:804–20
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. (2010). Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 10:9–22
   PubMed Web of Science ®Google Scholar
• Farokhzad OC, Langer R. (2009). Impact of nanotechnology on drug delivery. ACS Nano 3:16−20
   PubMed Web of Science ®Google Scholar
• Gao H, Qian J, Yang Z, et al. (2012). Whole-cell SELE X aptamer-functionalised poly-(ethyleneglycol)-poly(ɛ-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials 33:6264–72
   PubMed Web of Science ®Google Scholar
• Gerweck LE, Seetharaman K. (1996). Cellular pH gradient in tumor versus normal tissue: potential exploitation for the treatment of cancer. Cancer Res 56:1194–8
   PubMed Web of Science ®Google Scholar
• Gong C, Wei X, Wang X, et al. (2010). Biodegradable self-assembled PEG-PCL-PEG micelles for hydrophobic Honokiol delivery: I. Preparation and characterization. Nanotechnology 21:215103
   PubMed Web of Science ®Google Scholar
• Goodman TT, Olive PL, Pun SH. (2007). Increased nanoparticle penetration in collagenase-treated multicellullar spheroids. Int J Nanomed 2:265–74
   PubMed Web of Science ®Google Scholar
• Goodman TT, Ng CP, Pun SH. (2008). 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers. Bioconjug Chem 19:1951–9
   PubMed Web of Science ®Google Scholar
• Hirsjarvi S, Passirani C, Benoit JP. (2011). Passive and active tumour targeting with nanocarriers. Curr Drug Discov Technol 8:188–96
   PubMedGoogle Scholar
• Humphries MJ. (2000). Integrin structure. Biochem Soc Trans 28:311–39
   PubMed Web of Science ®Google Scholar
• Hynes RO. (2002). Integrins: bidirectional, allosteric signaling machines. Cell 110:673–87
   PubMed Web of Science ®Google Scholar
• Iguchi A, Fukuda N, Takahashi T, et al. (2013). RNA binding properties of novel gene silencingpyrrole-imidazole polyamides. Biol Pharm Bull 36:1152–8
   PubMed Web of Science ®Google Scholar
• Iwasaki Y, Horiuchi T, Niwa O. (2001). Detection of electrochemical enzymatic reactions by surface plasmon resonance measurement. Anal Chem 73:1595–8
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. (2010). Cancer statistics. CA Cancer J Clin 60:277–300
   PubMed Web of Science ®Google Scholar
• Johnson MS, Lu N, Denessiouk K, et al. (2009). Integrins during evolution: evolutionary trees and model organisms. Biochim Biophys Acta 1788:779–89
   PubMed Web of Science ®Google Scholar
• Karlsson R, Fält A. (1997). Experimental design for kinetic analysis of protein–protein interactions with surface plasmon resonance biosensors. J Immunol Methods 200:121–33
   PubMed Web of Science ®Google Scholar
• Kataoka K, Matsumoto T, Yokoyama M, et al. (2000). Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-l-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 64:143–53
   PubMed Web of Science ®Google Scholar
• Khan JA, Kudgus RA, Szabolcs A, et al. (2011). Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo. PLoS One 6:e20347
   PubMed Web of Science ®Google Scholar
• Kim B, Han G, Toley BJ, et al. (2010). Tuning payload delivery in tumour cylindroids using gold nanoparticles. Nat Nanotechnol 5:465–72
   PubMed Web of Science ®Google Scholar
• Lin R, Chang H. (2008). Recent advances in three-dimensional multicellular spheroid culture for biomedical research. J Biotechnol 3:1172–84
   Google Scholar
• Millard M, Odde S, Neamati N. (2011). Integrin targeted therapeutics. Theranostics 1:154–88
   PubMed Web of Science ®Google Scholar
• Minchinton AI, Tannock IF. (2006). Drug penetration in solid tumours. Nat Rev Cancer 6:583–92
   PubMed Web of Science ®Google Scholar
• Nagae M, Re S, Mihara E, et al. (2012). Crystal structure of α5β1 integrin ectodomain: atomic details of the fibronectin receptor. J Cell Biol 197:131–40
   PubMed Web of Science ®Google Scholar
• Nakahara H, Nomizu M, Akiyama SK, et al. (1996). A mechanism for regulation of melanoma invasion. Ligation of alpha6beta1 integrin by laminin G peptides. J Biol Chem 271:27221–4
   PubMed Web of Science ®Google Scholar
• Nakamura I, Duong T, Rodan SB, Rodan GA. (2007). Involvement of alpha(v)beta3 integrins in osteoclast function. J Bone Miner Metab 25:337–44
   PubMed Web of Science ®Google Scholar
• Nam HY, Kwon SM, Chung H, et al. (2009). Cellular uptake mechanism and intracellular fate of hydrophobically modified glycol chitosan nanoparticles. J Control Release 135:259–67
   PubMed Web of Science ®Google Scholar
• Ni H, Gagne D, Basora N, Beaulieu JF. (2001). Up-regulation of the α6β4 integrin in human colon cancer cells. Gastroenterology 120:A61
   Google Scholar
• Perrault SD, Walkey C, Jennings T, et al. (2009). Mediating tumor targeting efficiency of nanoparticles through design. Nano Lett 9:1909–15
   PubMed Web of Science ®Google Scholar
• Ray MR, Lakshmi C, Deb C, et al. (2000). Modulatory effect of dopamine on doxorubicin-induced myelosuppression. Comp Haematol Int 10:212–20
   Google Scholar
• Reddy KV, Mangale SS. (2003). Integrin receptors: the dynamic modulators of endometrial function. Tissue Cell 35:260–73
   PubMed Web of Science ®Google Scholar
• Robinson SD, Hodivala-Dilke KM. (2011). The role of beta3-integrins in tumor angiogenesis: context is everything. Curr Opin Cell Biol 23:630–7
   PubMed Web of Science ®Google Scholar
• Steinherz LJ, Steinherz PG, Tan CT, et al. (1991). Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J Am Med Assoc 266:1672–7
   PubMed Web of Science ®Google Scholar
• Stefanich EG, Danilenko DM, Wang H, et al. (2011). A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 162:1855–70
   PubMed Web of Science ®Google Scholar
• Sun Y, Yan X, Yuan T, et al. (2010). Disassemblable micelles based on reduction-degradable amphiphilic graft copolymers for intracellular delivery of doxorubicin. Biomaterials 31:7124–31
   PubMed Web of Science ®Google Scholar
• Sutherland R. (1988). Cell and environment interactions in tumor microregions: the multicell spheroid model. Science 240:177–84
   PubMed Web of Science ®Google Scholar
• Weeraratne DK, Lofgren J, Dinnogen S, et al. (2013). Development of a biosensor-based immunogenicity assay capable of blocking soluble drug target interference. J Immunol Methods 396:44–55
   PubMed Web of Science ®Google Scholar
• Wei Y, Xu S, Wang F, et al. (2014). A novel combined micellar system of lapatinib and paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro. J Pharm Sci 104:165–77
   PubMed Web of Science ®Google Scholar
• Wilder RL. (2002). Integrin alphaV beta3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases. Ann Rheum Dis 61:ii96–9
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2013). Global cancer rates could increase by 50% to 15 million by 2020. Available from: http://www.who.int/mediacentre/news/releases/2003/pr27/en/ [last accessed 9 Aug 2015]
   Google Scholar
• Wong TW, Colombo G, Sonvico F. (2011). Pectin matrix as oral drug delivery vehicle for colon cancer treatment. AAPS Pharm Sci Tech 12:201–14
   PubMed Web of Science ®Google Scholar
• Xu W, Cui Y, Ling P, Li LB. (2012). Preparation and evaluation of folate-modified cationic pluronic micelles for poorly soluble anticancer drug. Drug Deliv 19:208–19
   PubMed Web of Science ®Google Scholar
• Yamada K, Cukierman E. (2007). Modeling tissue morphogenesis and cancer in 3D. Cell 130:601–10
   PubMed Web of Science ®Google Scholar
• Zhan C, Gu B, Xie C, et al. (2010a). Cyclic RGD conjugated poly (ethylene glycol)-co-poly (lactic acid) micelle enhances paclitaxel anti-glioblastoma effect. J Control Release 143:136–42
   PubMed Web of Science ®Google Scholar
• Zhan C, Yan Z, Xie C, Lu W. (2010b). Loop 2 of Ophiophagus hannah toxin b binds with neuronal nicotinic acetylcholine receptors and enhances intracranial drug delivery. Mol Pharm 7:1940–7
   PubMed Web of Science ®Google Scholar
• Zhang J, Gao J, Tan X, et al. (2010a). Effects of down-regulation of integrin-β1 expression on migration and hepatic metastasis of human colon carcinoma. J Huazhong Univ Sci Technol 30:464–9
   PubMed Web of Science ®Google Scholar
• Zhang HZ, Li XM, Gao FP, et al. (2010b). Preparation of folate-modified pullulan acetate nanoparticles for tumor-targeted drug delivery. Drug Deliv 17:48–57
   PubMed Web of Science ®Google Scholar
• Zhao M, Li A, Chang J, et al. (2013). Develop a novel superparamagnetic nano-carrier for drug delivery to brain glioma. Drug Deliv 20:95–101
   PubMed Web of Science ®Google Scholar
• Ziolkowska K, Kwapiszewski R, Brzozka Z. (2011). Microfluidic devices as tools mimicking in vivo environment. New J Chem 35:979–90
   Web of Science ®Google Scholar